12:00 AM
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

RQ-00000004: Phase I data

A U.S. Phase I trial in healthy male volunteers showed that single ascending-doses of up to 300 mg oral RQ-00000004 were well tolerated. Additionally, single doses...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >